0001193125-25-269678
SEC filingRevenue declined 10.4% QoQ due to strategic shift from Mainland China, but gross margin improved 970bps to 42.3% on favorable mix.
For the three months ended September 30, 2025, net sales decreased 10.4% to $18.2 million from $20.3 million in the same period of 2024, driven by a strategic de-emphasis of Mainland China sales, which plunged 87.9% to $1.2 million. However, sales outside Mainland China grew 66.8% to $17.0 million, reflecting a deliberate shift toward higher-margin opportunities. Gross profit rose 16.4% to $7.7 million, and gross margin expanded 970 basis points to 42.3%, benefiting from a more favorable product and customer mix. Loss from operations narrowed slightly to $10.0 million from $10.1 million, as lower research and development expenses (down 7.1%) were offset by a 24.0% increase in selling, general and administrative expenses, largely due to $1.0 million in IPO-related stock-based compensation and $0.8 million in one-time cash bonuses. Net loss improved to $9.0 million from $9.4 million, aided by a 57.2% increase in other income, net, primarily from interest income on IPO proceeds.
The MD&A details two primary geographic segments: Mainland China and outside Mainland China. Mainland China net sales fell 87.9% year-over-year to $1.2 million in Q3 2025, and 83.8% for the nine-month period to $4.2 million, as the company intentionally reduced exposure due to geopolitical concerns and pricing pressures from subsidized local competitors. Conversely, sales outside Mainland China increased 66.8% to $17.0 million in Q3 2025 and 61.2% to $47.5 million for the nine months, supported by higher gross margins. Gross profit from non-Mainland China customers reached $7.2 million in Q3 2025 versus $5.7 million in the prior-year quarter, underscoring the margin benefit of the geographic mix shift. The company expects this trend to continue, with Mainland China sales falling to just 7% of total net sales in Q3 2025 from 50% a year earlier.
Management's outlook is implicit rather than explicit, with no formal revenue or margin guidance provided. The discussion emphasizes a continued strategic pivot away from Mainland China toward higher-margin geographies, including the United States, Europe, and Asia (excluding Mainland China). Key strategic priorities include expanding into new markets such as medical/healthcare, industrial edge, and smart homes and buildings. The company expects to increase research and development expenditures to support product development (e.g., Apollo6, Atomiq) and to incur higher selling, general and administrative costs associated with being a public company. Liquidity is robust, with $146.5 million in cash as of September 30, 2025, supplemented by $102.7 million in net IPO proceeds. Management believes existing cash and anticipated cash from operations will be sufficient to fund operations for at least the next twelve months, though future capital needs may require additional financing.
As of September 30, 2025, Ambiq Micro reported cash and cash equivalents of $146.5 million, a significant increase from $61.0 million at December 31, 2024, driven primarily by net proceeds of $99.8 million from its initial public offering (IPO) in July 2025. Total assets stood at $186.7 million, with stockholders' equity of $169.8 million (versus a deficit of $292.4 million at year-end 2024). The company's total debt is limited to lease liabilities of $0.8 million ($0.4 million short-term and $0.4 million long-term). Inventory increased slightly to $16.1 million from $15.0 million, consisting of $0.0 million raw materials, $10.1 million work in progress, and $6.0 million finished goods.
The Notes disclose total manufacturing purchase commitments of $6.3 million as of September 30, 2025. These commitments stem from agreements with third-party foundries and contract manufacturers, though purchase orders can generally be canceled or rescheduled upon mutual agreement. No other material contractual obligations (e.g., debt maturities, operating leases beyond recognized liabilities) were detailed.
No share buyback programs, dividends, or new debt issuances were disclosed in the Notes. The IPO provided $99.8 million in net proceeds after underwriting discounts and commissions. Capital expenditures are not explicitly detailed in the Notes (the cash flow statement shows $1.2 million in software and equipment purchases and $3.7 million in intangible asset purchases for the nine months ended September 30, 2025, but these are not part of the Notes commentary). Stock-based compensation totaled $3.7 million for the nine months ended September 30, 2025, with an additional $0.3 million from option acceleration.
Ambiq operates as a single reportable segment. Revenue is disaggregated by end customer geography: for the nine months ended September 30, 2025, the United States accounted for $44.8 million (86% of total), China $4.2 million (8%), and Rest of World $2.7 million (5%). By shipment destination, Taiwan represented $20.3 million, China $20.5 million, Singapore $7.3 million, and Rest of World $3.8 million. The company depends on three end customers that together contributed 85% of revenue in the nine-month period. The loss of any significant customer could materially impact results.
For the nine months ended September 30, 2025, Ambiq Micro reported a net loss of $25.8 million, while net cash used in operating activities was $15.6 million. The improvement in operating cash flow compared to the prior year (net loss of $29.5 million and operating cash outflow of $21.7 million) reflects a narrowing of the gap between net loss and cash burn, driven by non-cash charges (depreciation and amortization of $5.6 million, stock-based compensation of $3.7 million) and a $3.5 million decrease in accounts receivable. However, inventories increased by $1.1 million, and accounts payable declined by $1.0 million, indicating some working capital drag.
Capital expenditures (capex) were $1.2 million, modest relative to the operating cash deficit. The company did not report free cash flow, but the combination of operating cash outflow and capex implies negative free cash flow. Financing activities provided $105.9 million, primarily from the IPO ($99.8 million net) and warrant exercises ($5.7 million), which bolstered the cash balance to $146.5 million at period end.
No share repurchases or dividends were disclosed. The company's cash flow profile remains dependent on external financing to fund operations and investment.